We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma Biologics (ADMA - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adma Biologics is a member of the Medical sector. This group includes 1003 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ADMA's full-year earnings has moved 6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ADMA has returned about 21.9% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -3.8% on a year-to-date basis. This shows that Adma Biologics is outperforming its peers so far this year.
Another stock in the Medical sector, Agilon Health (AGL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 194.7%.
The consensus estimate for Agilon Health's current year EPS has increased 22.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adma Biologics belongs to the Medical - Biomedical and Genetics industry, a group that includes 509 individual stocks and currently sits at #75 in the Zacks Industry Rank. This group has lost an average of 6.4% so far this year, so ADMA is performing better in this area.
Agilon Health, however, belongs to the Medical Services industry. Currently, this 58-stock industry is ranked #80. The industry has moved -0.5% so far this year.
Adma Biologics and Agilon Health could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma Biologics (ADMA - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adma Biologics is a member of the Medical sector. This group includes 1003 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ADMA's full-year earnings has moved 6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ADMA has returned about 21.9% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -3.8% on a year-to-date basis. This shows that Adma Biologics is outperforming its peers so far this year.
Another stock in the Medical sector, Agilon Health (AGL - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 194.7%.
The consensus estimate for Agilon Health's current year EPS has increased 22.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adma Biologics belongs to the Medical - Biomedical and Genetics industry, a group that includes 509 individual stocks and currently sits at #75 in the Zacks Industry Rank. This group has lost an average of 6.4% so far this year, so ADMA is performing better in this area.
Agilon Health, however, belongs to the Medical Services industry. Currently, this 58-stock industry is ranked #80. The industry has moved -0.5% so far this year.
Adma Biologics and Agilon Health could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.